{"nctId":"NCT03463915","briefTitle":"Clinical Trial Comparing Two Bladder Instillations for IC/BPS","startDateStruct":{"date":"2019-01-25","type":"ACTUAL"},"conditions":["Interstitial Cystitis","Bladder Pain Syndrome"],"count":90,"armGroups":[{"label":"Bladder instillation WITH triamcinolone acetonide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bladder instillation WITH triamcinolone acetonide"]},{"label":"Bladder instillation WITHOUT triamcinolone acetonide","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Bladder instillation WITHOUT triamcinolone acetonide"]}],"interventions":[{"name":"Bladder instillation WITH triamcinolone acetonide","otherNames":[]},{"name":"Bladder instillation WITHOUT triamcinolone acetonide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women 18 years and older\n* Women with IC/BPS who have a score of â‰¥ 6 on either index (problem or symptom index) of the O'Leary-Sant questionnaire who have selected bladder instillations as part of their IC/BPS treatment\n* Suitability for follow-up\n\nExclusion Criteria:\n\n* Contraindications and/or allergies to the ingredients used in the bladder instillations\n* Diagnosis of idiopathic thrombocytopenic purpura\n* Does not desire to undergo bladder instillation therapy or unwilling to undergo bladder instillation therapy on schedule mandated by study\n* Have a known alternative diagnosis explaining bladder pain symptoms that would preclude the diagnosis of IC/BPS (e.g. radiation cystitis, active urinary tract infection with bacteria or fungus treated within last 2 weeks or diagnosed at index visit, bladder injury or trauma within the last 30 days)\n* Inability to speak or read English\n* Bladder instillation within the past 4 weeks","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire","description":"Total scores range: 0-36 (0= no symptoms to 36= the most severe symptoms)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"7.1"},{"groupId":"OG001","value":"-5.8","spread":"8.0"}]}]}]},{"type":"SECONDARY","title":"Pelvic Pain and Urgency/Frequency (PUF) Questionnaire","description":"Total scores range: 0-35 (0= no symptoms to 35= the most severe symptoms)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"5.1"},{"groupId":"OG001","value":"-2.7","spread":"5.5"}]}]}]},{"type":"SECONDARY","title":"Overactive Bladder Questionnaire (OAB-q)","description":"Total scores range: 0-100 (higher scores on the symptom-severity scale suggestive of greater severity of symptoms and higher scores on the quality-of-life scale suggestive of better quality of life)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.2","spread":"19.1"},{"groupId":"OG001","value":"-18.8","spread":"24.6"}]}]}]},{"type":"SECONDARY","title":"Pelvic Floor Distress Inventory (PFDI)","description":"20 question self-administered questionnaire on the presence and absence of pelvic floor symptoms. Score ranges from 0 (least distress) to 300 (most distress).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"9.5"},{"groupId":"OG001","value":"-6.4","spread":"9.7"}]}]}]},{"type":"SECONDARY","title":"Sexual Function Measured by the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) Questionnaire","description":"Measures sexual function in women with pelvic floor disorders. Queries about arousal, orgasm, partner-related issues, sexual quality, and desire. The tool also takes into account those who are not sexually active. The questionnaire was used in the study solely to determine if patients had improved dyspareunia (as a categorical variable).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Treatment Response as Measured by the Visual Analogue Scale (VAS) for Pain","description":"VAS is measured on marking on a 10-centimeter (cm) ruler (measured in cm, 0= no pain and 10= most severe pain possible)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"2.6"},{"groupId":"OG001","value":"-1.8","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With at Least One Adverse Event","description":"Adverse events will only be those determined to be related to the study drug","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":45},"commonTop":["Urethral pain","Urinary tract infection","Anxiety attack","Strong bladder spasms"]}}}